- Home
- SEGG vs GTBP Comparison
SEGG vs GTBP Comparison
Compare SEGG & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 17.7M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SEGG | GTBP |
|---|---|---|
| Price | $2.58 | $0.28 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 375.5K | ★ 441.4K |
| Earning Date | 05-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.56 | 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,779,057.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.26 |
| 52 Week High | $7.61 | $1.37 |
Technical Indicators
Market Signals| Indicator | SEGG | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 36.35 |
| Support Level | $0.76 | $0.26 |
| Resistance Level | $2.58 | $0.49 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.82 | 16.26 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is operated as a single-reporting unit focused on its lottery and gaming platform, and its organizational structure, internal reporting systems, and resource allocation processes were aligned accordingly.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.